# Deep Longevity

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/deep-longevity

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.deeplongevity.com
- Latest round: Series A (Jul 14, 2020)
- Investors on record: 6

## About

Deep Longevity, Ltd. leverages advanced health technology to provide a range of aging clocks that offer personalized insights into health and longevity through comprehensive biological and psychological assessments.Founded in 2020 and headquartered in San Diego, US, Deep Longevity, Ltd. specializes in health technology focused on aging assessments. The company has engaged in 2 deals, with the most recent deal occurring on September 2, 2020, when Regent Pacific Group Limited acquired Deep Longevity, Ltd. Financial terms of the acquisition were not disclosed. The CEO, Deepankar Nayak, leads the company's operations, contributing to its strategic direction.Deep Longevity specializes in advanced health technology, focusing primarily on its suite of aging clocks, which include Blood Age, Mind Age, Biometric Age, and Epigenetic Age. These products analyze various biological and psychological parameters, providing users with personalized health insights aimed at preventive care and early interventions. The aging clocks utilize comprehensive data from blood tests, DNA, and microbiome analyses, along with psychological surveys, to deliver precise assessments of individuals' biological age and health status. Targeted towards both enterprise clients and individual users, the company collaborates with universities, hospitals, and healthcare providers globally, including markets in North America, Europe, and Asia-Pacific. By enhancing users' understanding of their health and longevity, Deep Longevity's offerings empower individuals to optimize their lifestyles through tailored diet, exercise, and wellness recommendations.Deep Longevity's revenue model is centered around a Software as a Service (SaaS) framework, providing clients access to its aging clock platforms, SenoClock and SenoClock Gold. These platforms facilitate the generation of Biological Age predictions and Health Summary Reports for enterprise customers, including insurance companies, healthcare providers, and wellness programs. Transactions typically involve subscription agreements, where clients pay for access to the platforms and specific features that cater to their organizational needs. The company’s flagship products are integrated into these subscription services, allowing users to gain insights into their health based on specific assessments made by the aging clocks. Revenue is generated through direct B2B relationships, ensuring that enterprise clients can leverage the robust data provided for their customers and patients.Deep Longevity is focused on expanding its product offerings and market reach. Upcoming enhancements to the aging clock platforms are being designed, with new features aimed at improving user experience expected to launch in late 2023. The company plans to enter new geographical markets, particularly targeting regions in Asia-Pacific and Europe by the end of 2024. Recent funding from the acquisition will be directed towards developing these new products and expanding the sales team to facilitate entry into these new markets.

## Funding rounds

- Series A, Jul 14, 2020 — BOLD Capital Partners, Longevity Vision Holding, ETP Ventures LLC, Human Longevity and Performance Impact Venture Fund, Formic Ventures, LongeVC

## Investors

- BOLD Capital Partners (https://capitalatlas.ai/funds/bold-capital-partners) — Series A
- Longevity Vision Holding (https://capitalatlas.ai/funds/longevity-vision-holding) — Series A
- ETP Ventures LLC — Series A
- Human Longevity and Performance Impact Venture Fund (https://capitalatlas.ai/funds/human-longevity-and-performance-impact-venture-fund) — Series A
- Formic Ventures (https://capitalatlas.ai/funds/formic-ventures) — Series A
- LongeVC (https://capitalatlas.ai/funds/longevc) — Series A